Evidence map›Paper›PMID 40178520›Full record

ArticleThe Biochemical journal2025

Aurora A binds to the transactivation domain of c-Myc and recognizes the phosphorylated N-terminal degron motif.

Nidhi Joshi, Katie M Dunleavy, Kaitlin M Beel, Tiffany A Engel, Andrew R Thompson, Felix L John, David D Thomas, Nicholas M Levinson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Biochemical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. c-Myc: an emerging participant in heart failure.Frontiers in cardiovascular medicine · 2026
    Review
  4. The Yin-Yang balance of SIRT1 and SIRT2 in cancer metabolic remodeling.International journal of biological sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nidhi JoshiDepartment of Pharmacology and Masonic Cancer Center, University of Minnesota, 312 Church St. SE, Minneapolis, MN, 55455, USA.
Katie M DunleavyDepartment of Pharmacology and Masonic Cancer Center, University of Minnesota, 312 Church St. SE, Minneapolis, MN, 55455, USA.
Kaitlin M BeelDepartment of Pharmacology and Masonic Cancer Center, University of Minnesota, 312 Church St. SE, Minneapolis, MN, 55455, USA.
Tiffany A EngelDepartment of Pharmacology and Masonic Cancer Center, University of Minnesota, 312 Church St. SE, Minneapolis, MN, 55455, USA.
Andrew R ThompsonDepartment of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, 312 Church St. SE, Minneapolis, MN, 55455, USA.
Felix L JohnDepartment of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, 312 Church St. SE, Minneapolis, MN, 55455, USA.
David D ThomasDepartment of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, 312 Church St. SE, Minneapolis, MN, 55455, USA.
Nicholas M LevinsonDepartment of Pharmacology and Masonic Cancer Center, University of Minnesota, 312 Church St. SE, Minneapolis, MN, 55455, USA.

Funding

TRAINING PROGRAM IN MUSCLE RESEARCHT32AR007612 · NIAMS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI JAMES M ERVASTI, DAWN A LOWE · 2001 to 2026
$11.3M
A transformative drug discovery platform for allosteric kinase inhibitorsR01CA255513 · NCI · UNIVERSITY OF MINNESOTA · PI LEVINSON, NICHOLAS MARK, THOMAS, DAVID D · 2021 to 2025
$2.9M
Targeting allosteric scaffolding functions of Aurora kinase A in cancerR01CA244645 · NCI · UNIVERSITY OF MINNESOTA · PI LEVINSON, NICHOLAS MARK · 2021 to 2025
$1.7M
A transformative next-generation Orbitrap Tribrid system for the UMN and Upper MidwestS10OD028717 · OD · UNIVERSITY OF MINNESOTA · PI GRIFFIN, TIMOTHY J. · 2020 to 2020
$1.2M
Defining Mechanisms Governing Myc Stability and its Modulation by Aurora Kinase AK99GM157491 · NIGMS · UNIVERSITY OF MINNESOTA · PI DUNLEAVY, KATIE M. · 2024 to 2025
$250k
NCI NIH HHS R01 CA244645NCI NIH HHS R01 CA255513NIAMS NIH HHS T32 AR007612NIGMS NIH HHS K99 GM157491NIH HHS S10 OD028717
6 · The paper itself

Abstract

The oncoprotein c-Myc is overexpressed or mutated in a large fraction of human cancers. The stability of c-Myc is controlled by phosphorylation of T58 and S62 within a conserved degron motif in the N-terminal transactivation domain, which triggers recruitment of the SCF ubiquitin ligase. The kinase Aurora A (AurA) has been shown to bind to both c-Myc and its paralog N-Myc and to promote their stability by interfering with ubiquitination and degradation. Here we show, using NMR and FRET experiments, that AurA binds to c-Myc through several discrete interactions spanning 145 residues within its transactivation domain. AurA binding to c-Myc is enhanced by phosphorylation of the T58/S62 degron, demonstrating that the kinase recognizes the pool of c-Myc that has been marked for degradation by the ubiquitin proteasome pathway. Although AurA binds to segments of c-Myc flanking the degron, it does not appear to form extensive interactions with the phosphorylated degron itself, potentially leaving it accessible on the AurA surface. These observations establish a foundation for understanding the role of AurA in regulating c-Myc ubiquitination and degradation.

Indexed as

Aurora Ac-MycfluorescenceNMRprotein kinase

Identifiers

PMID40178520
PMCPMC12203944

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.